Ibrutinib (PCI-32765) is a potent covalent inhibitor of BTK that was recently approved by the Food and Drug Administration for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia33. The gene discussed is BTK; the disease is mantle cell lymphoma.